B+
Bull case
20%
Probability
Target price
$4.25
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
SRTS
Sensus HealthcareFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
60%
Probability
Target price
$3.22
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$1.69
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-25
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.6
Score
AI commentary
Company-reported pipeline and reimbursement developments are encouraging, but the Q2 revenue decline tempers the tone. The packet does not verify the post-release share-price reaction, analyst revisions or current social coverage; zero values in the sentiment fields denote unavailable data, not neutral observations. Director open-market purchases in August are disclosed but do not establish operating improvement. [#SEC-FORM4-2026-08-25] [#SEC-FORM4-2026-08-31]
RankAlpha Sentiment Codex - 2026-09-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-24eventProposed hospital-based reimbursement increaseHigh impact
The company reported that CMS proposed a 26% increase in the hospital-based SRT delivery code. Finalization could improve provider economics, but the proposal is not an enacted reimbursement change. [#SEC-8K-2026-08-13]
2026-12-24catalystQ3 recognition of eight previously sold unitsHigh impact
Sensus reported Q2 revenue of $2.3 million, down $5.0 million year over year. Financing-approval timing prevented recognition of eight units in Q2; the company said the approvals were subsequently completed and the revenue would be recognized in Q3. This would recover timing-related revenue, not establish incremental demand. [#8-K-2026-08-13] [#SEC-8K-2026-08-13]
2027-09-25catalystConvert CPT-related interest into sustained salesHigh impact
Management reported stronger customer engagement and a sales pipeline following CPT-code implementation, including interest from physician groups and health systems. Sustained unit sales and revenue growth remain unproven after the Q2 decline. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-25 • Updated nightlySource: Internal modelMethodology